ANA Therapeutics
Investigating niclosamide as a treatment for COVID-19
ANA Therapeutics operates in therapeutics based in United States, founded in 2020.
Profile
ANA Therapeutics developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19. ANA Therapeutics was acquired by NeuroBo Pharmaceuticals in 2020.
As a business in therapeutics, ANA Therapeutics is listed here with the public details available about it.
The company is recorded as being based in United States.
It is recorded at the SOSV portfolio company stage.
Its team size is recorded as 2-10 employees.
| Sector | Therapeutics |
|---|---|
| Country | United States |
| Founded | 2020 |
| Employees | 2-10 |
| Stage | SOSV portfolio company |
Website: www.neurobopharma.com
Full contact details are available to registered Pixilab members.
Create a free account
Create a free account